A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma

Inclusion Criteria:

• Patient diagnosed with chronic persistent asthma
• Annual uncontrollable time ≥ 3 months
• Patients who have given written informed consent

Exclusion Criteria:

• History of upper upper/lower respiratory infection in the previous 1 months
• History of long-term controller medication use for asthma (oral corticosteroid orintravenous corticosteroids therapy) within the preceding 1 months
• History of antibiotic use in the previous 1 months
• History of life-threatening asthma
• History of chronic lung diseases other than asthma, including but not limited tochronic obstructive pulmonary disease, bronchiectasis, emphysema, tuberculosis,sarcoidosis, pulmonary fibrosis, lung cancer, etc
• History of serious disease of the heart and cerebrovascular disease
• History of severe liver or renal dysfunction or disease
• History of severe disease in the hematopoietic system
• History of immunodeficiency (including, but not limited to, HIV positive detection, orother acquired or congenital immunodeficiency disease, or organ transplant history)
• History of any other condition (such as known drug or alcohol abuse or psychiatricdisorder) which, in the opinion of the investigator, may preclude the patient fromfollowing and completing the protocol
• Are currently enrolled in, or discontinued within the last 30 days from, a clinicaltrial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolledin any other type of medical research judged not to be scientifically or medicallycompatible with this study
• History of allergies to the component of the investigated drugs
• Smoking within the past year
• Contraindication to induced sputum collection method on history or examination
• Any serious medical condition which, in the opinion of the Investigator, would pose asignificant risk to the patient or interfere with the interpretation of safety,efficacy, or pharmacodynamic data